We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

33 hedge funds and large institutions have $49.5M invested in Marker Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

773% more capital invested

Capital invested by funds: $5.67M → $49.5M (+$43.8M)

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

19.23% more ownership

Funds ownership: 22.54% → 41.77% (+19%)

18% more funds holding

Funds holding: 28 → 33 (+5)

Holders
33
Holders Change
+5
Holders Change %
+17.86%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.24M
2
BOCH
Blue Owl Capital Holdings
New York
+$1.96M
3
NMC
NEA Management Company
Maryland
+$1.96M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.17M
5
LPL Financial
LPL Financial
California
+$282K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$53.9K
2
Citadel Advisors
Citadel Advisors
Florida
-$36.8K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$15.5K
4
Morgan Stanley
Morgan Stanley
New York
-$10.8K
5
BlackRock
BlackRock
New York
-$8.66K
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
1
Alyeska Investment Group
Illinois
$38.5M +$3.24M +915,591 New
NMC
2
NEA Management Company
Maryland
$5.06M +$1.96M +554,250 +52%
BOCH
3
Blue Owl Capital Holdings
New York
$1.72M +$1.96M +554,250 New
ACM
4
Aisling Capital Management
New York
$1.01M +$39.3K +11,084 +4%
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$958K +$1.17M +331,670 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$756K – – –
LPL Financial
7
LPL Financial
California
$248K +$282K +79,730 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$235K +$14.6K +4,119 +6%
AAM
9
AR Asset Management
California
$229K – – –
Northern Trust
10
Northern Trust
Illinois
$168K +$76.9K +21,703 +67%
Renaissance Technologies
11
Renaissance Technologies
New York
$125K +$1.06K +300 +0.8%
State Street
12
State Street
Massachusetts
$65.1K – – –
I
13
INVST
Indiana
$62.9K +$839 +237 +1%
Creative Planning
14
Creative Planning
Kansas
$53.8K – – –
BlackRock
15
BlackRock
New York
$51.5K -$8.66K -2,447 -13%
EGM
16
Engineers Gate Manager
New York
$51.1K +$58.2K +16,442 New
Millennium Management
17
Millennium Management
New York
$50.1K +$57K +16,108 New
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$49.4K -$15.5K -4,378 -22%
MAA
19
Matrix Asset Advisors
New York
$46.6K – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$26.5K +$5.13K +1,450 +20%
Bank of America
21
Bank of America
North Carolina
$10K +$2.13K +601 +23%
RAM
22
Riggs Asset Management
Pennsylvania
$4.01K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$3.92K -$878 -248 -16%
US Bancorp
24
US Bancorp
Minnesota
$2.61K – – –
Morgan Stanley
25
Morgan Stanley
New York
$1.11K -$10.8K -3,050 -89%
1
2

MRKR Hedge Fund Activity: Q4 2024 in Review

33 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2024, worth a combined $49.5M — up 773% from $5.67M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new MRKR positions and 3 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.24M. The largest seller was UBS Group, exiting entirely with an estimated $53.9K sold.

  • 33 institutional investors held Marker Therapeutics (MRKR) as of Q4 2024, up from 28 in Q3 2024.
  • Funds reported $49.5M of Marker Therapeutics stock for Q4 2024, up 773% quarter-over-quarter.
  • 8 funds opened new Marker Therapeutics positions in Q4 2024 and 3 closed out, a net change of +5 holders.
  • The largest Marker Therapeutics buyer in Q4 2024 was Alyeska Investment Group, an estimated $3.24M added.
  • The largest Marker Therapeutics seller in Q4 2024 was UBS Group, an estimated $53.9K sold.

Based on aggregated 13F filings for Q4 2024.